ويغوفي وحقن التنحيف: تحذيرات من فقدان البصر وآثار جانبية خطيرة

Berlin, Germany – A growing number of reports are raising concerns about a potential link between the popular weight-loss drug Wegovy and a rare eye condition that can lead to sudden vision loss. While not yet definitively established, the emerging evidence is prompting medical professionals to urge caution and increased vigilance among patients using the medication.

The condition, often referred to as “eye stroke” – though medically known as non-arteritic anterior ischemic optic neuropathy (NAION) – involves a disruption of blood flow to the optic nerve, potentially causing rapid and irreversible vision impairment. Recent analyses, including studies highlighted in reports from 24.ae, Erem News and Al Arabiya, suggest that individuals taking Wegovy may face a higher risk of developing NAION compared to those using other GLP-1 receptor agonists like Ozempic.

What is “Eye Stroke” and Why the Concern?

It’s crucial to understand that “eye stroke” is not a formal medical diagnosis. As reported by 24.ae, the term is commonly used to describe NAION. This condition occurs when blood flow to the optic nerve is compromised, leading to damage and potential vision loss. The exact mechanisms behind NAION are complex and not fully understood, but factors like high blood pressure, diabetes, and certain medications can increase the risk.

The recent alarm stems from observations suggesting a disproportionate number of Wegovy users reporting instances of NAION. A study highlighted by Al Arabiya indicated that Wegovy appears to be associated with a higher incidence of these vision-related events than Ozempic. Specifically, the analysis suggested that men taking Wegovy had a three-fold increased risk of experiencing an “eye stroke” compared to those on other semaglutide medications. This finding is particularly concerning given the increasing popularity of Wegovy as a weight-loss aid.

Wegovy and Ozempic: Understanding the Differences

Both Wegovy and Ozempic contain semaglutide, a GLP-1 receptor agonist originally developed to treat type 2 diabetes. These medications perform by mimicking the effects of a natural hormone that regulates appetite and blood sugar levels. While both drugs have proven effective in promoting weight loss, they differ in dosage and intended use. Ozempic is typically prescribed for diabetes management, while Wegovy is specifically approved for chronic weight management in individuals with obesity or who are overweight with at least one weight-related health condition.

The differing dosages may play a role in the observed risk disparity. Wegovy contains a higher dose of semaglutide than Ozempic. The increased dosage, while potentially leading to greater weight loss, could also be contributing to the elevated risk of NAION, even though the precise relationship remains under investigation. As Erem News reported, the increased risk associated with Wegovy is prompting further scrutiny of the drug’s safety profile.

Symptoms and What to Do If You Experience Vision Changes

Recognizing the symptoms of NAION is critical for prompt diagnosis and potential intervention. Symptoms can include sudden blurred vision, decreased color vision, and pain in or around the eye. The vision loss associated with NAION is often rapid in onset and can affect one or both eyes.

If you are taking Wegovy or Ozempic and experience any sudden changes in your vision, it is imperative to seek immediate medical attention. A thorough eye examination by an ophthalmologist is necessary to determine the cause of the vision changes and rule out other potential conditions. Early diagnosis and treatment may assist minimize the extent of vision loss, although recovery is not always guaranteed.

What Do the Experts Say?

Medical experts are urging both patients and healthcare providers to be aware of the potential risk. While the absolute risk of NAION remains low, the observed association with Wegovy warrants careful consideration. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) are currently reviewing the available data to assess the potential link and determine if any regulatory action is necessary.

Dr. Fatima Al-Kindi, an ophthalmologist at Al-Jazeera Hospital in Abu Dhabi, emphasized the importance of patient education. “It’s vital that individuals taking these medications are informed about the potential risk of vision loss and know to seek immediate medical attention if they experience any concerning symptoms,” she stated in a report by Al Arabiya. She also noted that individuals with pre-existing risk factors for NAION, such as high blood pressure or glaucoma, may be at even greater risk.

Beyond Wegovy: A Broader Look at GLP-1 Receptor Agonists

The concerns surrounding Wegovy have prompted a broader examination of the potential ocular side effects associated with all GLP-1 receptor agonists. While Wegovy appears to carry a higher risk, NAION has been reported in association with other medications in this class as well. Researchers are working to understand the underlying mechanisms that may contribute to these vision-related events.

Some theories suggest that the medications may affect blood flow regulation in the optic nerve, potentially increasing the risk of ischemia. Others propose that the rapid weight loss induced by these drugs may lead to fluid shifts that affect the optic nerve. Further research is needed to clarify these mechanisms and identify individuals who may be particularly susceptible.

What’s Next?

The EMA and FDA are expected to release further guidance on the use of Wegovy and other GLP-1 receptor agonists in the coming months. This guidance may include updated labeling information, recommendations for patient monitoring, and potential restrictions on the use of these medications in certain populations.

Ongoing research is crucial to better understand the risk-benefit profile of these drugs and to identify strategies for minimizing the potential for adverse events. Patients considering using Wegovy or Ozempic should discuss the potential risks and benefits with their healthcare provider to make an informed decision. The situation is evolving, and staying informed about the latest developments is essential for both patients and medical professionals.

As of March 19, 2026, regulatory bodies continue to monitor reports of NAION associated with GLP-1 receptor agonists. Patients are encouraged to report any vision changes to their healthcare provider immediately. Further updates will be provided as they become available.

Have you or someone you know experienced vision changes while taking Wegovy or Ozempic? Share your experiences and thoughts in the comments below. Please also share this article with anyone who may be considering using these medications.